CJC-1295 FDA Approval History: Why This Peptide Was Never Approved

CJC-1295 Has Never Received FDA Approval

No version of CJC-1295 has been approved by the U.S. Food and Drug Administration. There is no FDA-approved label, no listed NDA or BLA in the Drugs@FDA database, and no commercial brand name tied to a marketing authorization.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified form of GRF(1-29) with four amino acid substitutions designed to resist enzymatic degradation [1]. ConjuChem Biotechnologies, the Montreal-based company that developed the Drug Affinity Complex (DAC) conjugated version, conducted early-phase clinical trials between 2004 and 2006. Those trials demonstrated that the peptide could produce sustained elevations in growth hormone (GH) and insulin-like growth factor 1 (IGF-1) after a single subcutaneous injection [1][2]. The program never advanced to Phase III.

The distinction matters for patients and clinicians. An unapproved peptide has no FDA-reviewed prescribing information, no standardized manufacturing requirements beyond pharmacy-level compounding standards, and no post-market surveillance system tracking adverse events at scale. The Endocrine Society has not issued clinical practice guidelines endorsing CJC-1295 for any indication [3].

What Is CJC-1295 and How Does It Work?

CJC-1295 belongs to a class of synthetic peptides that mimic the first 29 amino acids of endogenous GHRH with targeted substitutions at positions 2, 8, 15, and 27 to prevent dipeptidyl peptidase-IV (DPP-IV) cleavage [1]. The result is a molecule that binds to GHRH receptors on anterior pituitary somatotrophs and triggers pulsatile GH secretion.

Two forms circulate in clinical and compounding contexts. CJC-1295 with DAC uses a maleimidopropionic acid linker that binds irreversibly to serum albumin after injection, extending the half-life from roughly 30 minutes to approximately 5.8 to 8.1 days [1]. CJC-1295 without DAC (sometimes called "mod GRF 1-29" or "CJC-1295 no DAC") retains the amino acid substitutions but lacks the albumin-binding moiety, resulting in a much shorter half-life of roughly 30 minutes.

The pharmacologic rationale for CJC-1295 centered on providing sustained GH stimulation without the supraphysiologic peaks associated with exogenous GH injections. In the Teichman et al. trial, a single 60 mcg/kg dose of CJC-1295 DAC produced a 46% mean increase in IGF-1 levels that persisted for up to 28 days [1]. Pulsatile GH secretion. That pattern mimicked physiologic GH release more closely than daily recombinant GH injections.

Clinical Trial History: What the Data Show

The published clinical evidence for CJC-1295 rests primarily on two Phase I/II studies conducted in the mid-2000s and published in the Journal of Clinical Endocrinology & Metabolism.

Teichman et al. (2006) enrolled 56 healthy adults aged 21 to 61 in a dose-escalation study of CJC-1295 DAC [1]. Subjects received single or multiple subcutaneous doses ranging from 30 to 120 mcg/kg over 28 days. Mean GH levels increased 2- to 10-fold depending on dose and timing, while mean IGF-1 levels rose by 36% to 69% above baseline. The elevations in IGF-1 persisted for 6 to 14 days after a single injection. Injection site reactions occurred in approximately 8% of subjects, and transient flushing, dizziness, and headache were reported at higher doses [1].

Alba et al. (2006) studied repeated weekly or biweekly dosing of CJC-1295 DAC in 21 healthy subjects over a longer observation period [2]. IGF-1 levels remained elevated by 30% to 45% with repeated dosing, without evidence of tachyphylaxis over the study period. GH pulsatility was preserved, which the authors noted as a potential advantage over continuous GH administration [2].

Neither study included patients with growth hormone deficiency. Neither was designed to assess clinical endpoints like body composition, bone density, or functional capacity. The evidence base remains limited to short-term biomarker data in healthy volunteers.

Why CJC-1295 Development Stalled

Several factors converged to halt the path toward FDA approval.

ConjuChem Biotechnologies reported a death during clinical development of CJC-1295 DAC. The company disclosed in regulatory filings that a participant in one of its peptide programs died, though the causal relationship to the study drug was not definitively established in public records. That event, combined with the company's financial constraints, effectively ended the development program. ConjuChem filed for creditor protection in 2008 and its assets were subsequently sold [4].

No other pharmaceutical company has since acquired the CJC-1295 development program or filed an IND with the FDA for a new clinical trial. The peptide entered a regulatory limbo that persists today: studied enough to generate interest among clinicians and patients, but far short of the Phase III efficacy and safety data required for an NDA or BLA submission.

For comparison, tesamorelin (Egrifta), another GHRH analog, completed full Phase III development and received FDA approval in 2010 for lipodystrophy in HIV-infected patients [5]. That approval required two randomized, double-blind, placebo-controlled trials (N=816 combined) and a comprehensive safety database. CJC-1295 has nothing comparable.

FDA Regulatory Actions on Compounded Peptides

The FDA's relationship with compounded CJC-1295 has shifted significantly since 2023. Understanding this shift requires context about pharmaceutical compounding law.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacies may compound medications using bulk drug substances if the substance meets specific criteria and the prescription is for an individually identified patient [6]. CJC-1295 has been available through this pathway, with compounding pharmacies sourcing bulk peptide and preparing patient-specific doses.

In June 2023, FDA began a broader review of peptides commonly prepared by compounding pharmacies. The agency published a list of bulk drug substances under evaluation and convened its Pharmacy Compounding Advisory Committee (PCAC) to assess whether certain peptides, including several growth hormone secretagogues, met the criteria for continued use under 503A [6]. FDA's concern centered on peptides that are structurally complex, present stability challenges during compounding, and lack adequate safety data to support their use outside of approved product frameworks.

By early 2024, FDA had removed several peptides from the categories eligible for compounding. While the specific regulatory status of CJC-1295 continues to evolve, the trend is clear: FDA is tightening oversight of compounded peptides that have never gone through the standard approval process. Dr. Janet Woodcock, former FDA Principal Deputy Commissioner, stated in 2023 that "patients deserve the same assurance of safety and quality whether a drug is commercially manufactured or compounded" [6].

Clinicians prescribing CJC-1295 through compounding pharmacies should verify current 503A eligibility before writing new prescriptions, as enforcement actions may restrict access without advance notice.

Current Legal Status of CJC-1295

The legal status of CJC-1295 occupies a gray zone that confuses patients and clinicians alike.

CJC-1295 is not a scheduled controlled substance under the DEA's Controlled Substances Act. It is not illegal to possess. It is also not FDA-approved, which means it cannot be marketed, advertised, or sold as a drug with specific therapeutic claims. The peptide is available through three channels, each with different legal standing.

Compounding pharmacies operating under 503A can prepare CJC-1295 with a valid patient-specific prescription, provided the bulk substance remains on FDA's permissible list. This is the most legally defensible access route. Research chemical suppliers sell CJC-1295 labeled "for research use only, not for human consumption." This labeling creates legal separation from drug regulations, though the FDA has issued warning letters to companies marketing research peptides with implied therapeutic intent [6]. Online gray-market vendors operating outside U.S. jurisdiction sell finished peptide products directly to consumers. These products carry no regulatory oversight, no purity guarantees, and no legal protections for buyers.

The absence of an FDA-approved version means there is no official reference standard for purity, potency, or sterility. A 2019 analysis published in the Journal of the American Medical Association found that 11 of 44 peptide products purchased online contained inaccurate quantities of the labeled peptide, with some vials containing less than 60% of the stated dose [7].

Safety Profile Based on Available Evidence

Without Phase III data or post-market surveillance, the safety profile of CJC-1295 relies on limited clinical trial observations and case reports.

In the Teichman et al. trial, the most common adverse events were injection site reactions (erythema, induration, pruritus) in 8% of subjects, transient flushing (6%), dizziness (4%), and headache (4%) [1]. These events were mild to moderate and self-limiting. No serious adverse events were attributed to the study drug in the published data, though the program-level death reported by ConjuChem is not described in detail in the peer-reviewed literature.

Theoretical safety concerns include the sustained elevation of IGF-1. Epidemiologic data from the Nurses' Health Study and the Health Professionals Follow-up Study have shown that individuals in the highest quartile of circulating IGF-1 have a modestly increased relative risk of colorectal, breast, and prostate cancer [8]. Whether pharmacologically induced IGF-1 elevations carry the same risk as endogenously high levels is unknown. No cancer outcomes data exist for CJC-1295.

Other potential risks include water retention, carpal tunnel-like symptoms, joint stiffness, and hyperglycemia. These are class effects of GH axis stimulation rather than CJC-1295-specific findings. Long-term data beyond 90 days of exposure do not exist in published form. The Endocrine Society's 2019 guidelines on GH use in adults noted that "off-label use of GH secretagogues lacks the evidence base to support safety or efficacy claims" [3].

CJC-1295 DAC vs. CJC-1295 Without DAC

Clinicians and patients often conflate these two molecules, but they differ meaningfully in pharmacokinetics and clinical application.

CJC-1295 with DAC produces sustained, non-pulsatile GH elevation over days. The albumin-binding DAC moiety keeps circulating levels elevated continuously, which raises concerns about receptor desensitization and loss of the natural pulsatile GH secretion pattern that governs downstream signaling. In the Teichman et al. data, GH levels remained elevated above baseline for the full 14-day observation period after a single dose [1].

CJC-1295 without DAC (mod GRF 1-29) is cleared rapidly, producing a GH pulse that peaks within 30 minutes and returns to baseline within 2 to 3 hours. This pattern more closely resembles physiologic GHRH release. Many clinicians in the anti-aging and hormone-optimization space prefer the non-DAC form for this reason, often pairing it with a GH secretagogue peptide like ipamorelin to amplify the GH pulse.

Neither form has been studied in head-to-head trials. Neither has been evaluated in patients with diagnosed growth hormone deficiency. The pharmacokinetic differences are well-characterized from the Phase I/II data, but clinical outcome differences remain speculative.

What Would FDA Approval Require?

For any company to bring CJC-1295 to market as an FDA-approved drug, the regulatory pathway would demand substantially more data than currently exists.

A sponsor would need to file an IND, conduct Phase I safety studies in the target patient population (not just healthy volunteers), complete at least two adequate and well-controlled Phase III trials demonstrating efficacy for a specific indication, and compile a safety database of sufficient size and duration to characterize the risk-benefit profile [9]. For a biologic peptide, a BLA rather than an NDA would likely be the appropriate application.

The estimated cost of bringing a new drug from IND to approval exceeds $1 billion, with a median development timeline of 10 to 15 years [10]. Without patent protection (CJC-1295's original patents have expired), no pharmaceutical company has economic incentive to invest in this pathway. The peptide will likely remain unapproved indefinitely.

Patients considering CJC-1295 should discuss the regulatory status directly with their prescribing physician, confirm that their compounding pharmacy holds current 503A licensure and performs third-party potency and sterility testing, and understand that no FDA-reviewed safety or efficacy data support its use for any clinical indication.